David A. Frey
Lawyers
Associate in our IP, Tech & Commercial Transactions practice.
Experience highlights
Recent Representations
- RxSight $50 million follow-on offering
- ADC Therapeutics secondary offering
- TD SYNNEX $502 million secondary offering
- Priveterra Acquisition initial business combination with AEON Biopharma
- Tenaya Therapeutics $75 million stock and pre-funded warrants offering
- Snail $15 million IPO
- Akoya Biosciences $50 million at-the-market program
- Nayax direct listing
- Tenaya Therapeutics $75 million at-the-market offering
- RxSight $50 million at-the-market offering
- Infinera $373.75 million convertible senior notes offering
- Legend Biotech $403 million follow-on offering
- Baker Hughes sale of Nexus Controls to GE Gas Power
- GSK $3.3 billion acquisition of Affinivax
- SiTime at-the-market offering
- Acutus Medical sale of its left-heart access portfolio products
Education
J.D., Georgetown University Law Center
- Senior Editor, Georgetown Law Technology Review
B.S., Chemical Engineering, Bucknell University
Professional history
- Davis Polk since 2021
Qualifications and admissions
- State of New York